Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching from 3‑monthly LHRH agonists to 6‑monthly Decapeptyl SR 22.5 mg in advanced prostate cancer
2011-004213-16Phase 4Terminated
- Sponsor
- Ipsen
- Start
- Apr 2012
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of triptorelin in prostate cancer (PCa) (2 arms), sponsored by Ipsen. Primary endpoint: Primary Disease Control Endpoint. Started Apr 2012; status: terminated.
02
Drugs
triptorelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2011-004213-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004213-16.